A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors-Reference-Cited by-同舟云学术

A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors

Published:2020-01-31 Issue:11 Volume:26 Page:2497-2505
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Owonikoko Taofeek K.,Harvey R. Donald^ORCID,Carthon Bradley,Chen Zhengjia^ORCID,Lewis Colleen,Collins Hanna,Zhang Chao,Lawson David H.,Alese Olatunji B.^ORCID,Bilen Mehmet Asim,Sica Gabriel L.,Steuer Conor E.,Shaib Walid L.,Wu Christina,Harris Wayne B.,Akce Mehmet,Kudchagkar Ragini R.,El-Rayes Bassel F.^ORCID,Lonial Sagar,Ramalingam Suresh S.,Khuri Fadlo Raja

Funder

Novartis Oncology

Biostatistics and Bioinformatics

Cancer Tissue and Pathology

Winship Cancer Institute of Emory University

NIH

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling pathways in liver cancer: pathogenesis and targeted therapy;Molecular Biomedicine;2024-05-31

2. Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma;Cell Death Discovery;2024-04-15

3. Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are We on the Right Track?;Current Medicinal Chemistry;2024-04-04

4. NF1 alterations in cancers: therapeutic implications in precision medicine;Expert Opinion on Investigational Drugs;2023-10-03

5. Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis;Future Oncology;2023-06